GIOSTAR got the distinction of being named in the Insightscare.com Magazine as the “Company of the Month”. The Insightscare.com Magazine, which is one of the leading online healthcare magazines, published the journey of GIOSTAR becoming the world renowned institute of stem cell research and therapy.
The magazine also covered the interview given by Dr. Anand Srivastava – Chairman & Co-Founder of GIOSTAR for his expert opinion and future developments in the field of stem cell research and therapeutics.
The January-2021 edition of Insightscare.com also mentioned the able leadership of Mr. Deven Patel – CEO, President and Co-Founder of GIOSTAR who was honored with the USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the globe.
The magazine covered Dr. Anand Srivastava’s profound success and expertise in the field of stem cell biology, protein biochemistry, molecular biology, immunology, gene therapy and clinical research.
The magazine mentioned the big news of GIOSTAR FDA approval under compassionate use program and treatment of 53-year old critical COVID patient having recovered significantly after being infused with Stem Cells (MSCs).
Insightscares.com also reported how under the leadership of Mr. Deven Patel – GIOSTAR is heading the development of stem cell transplant program for four different state governments in India covering a population of approx. 155 million. The report further states that GIOSTAR in collaboration with the Gujarat government is building the world’s largest state-of-the-art stem cell treatment hospital in India.
The magazine also spelled out how GIOSTAR’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for over two decades. Overall, GIOSTAR is named as a company that is poised to become the largest institute of excellence in the field of stem cell research and therapy on the earth.
Civic Youth Conclave is a two-day virtual deliberation to be held on 9th and 10th January 2021. It is modeled on United Nations Conference with participants from all across the world. The Secretariat has envisioned this conference to be a platform to provide exposure to students and a safe space for them to put forth their cogent opinions. We are striving to make a difference and empower the youth for they are the future generation. We believe that MUN can lead to a deeper understanding of real-world problems and hence, lead to the youth finding solutions towards absolute world peace.
SAN DIEGO — A San Diego-based stem cell research institute believes its discovery may have saved the life of a COVID patient on death’s doorstep.
GIOSTAR infused a 53-year-old man in a coma with Mesenchymal stem-cells taken from an umbilical cord. Prior to that, all other treatments were failing.
“He was having a stroke, he was under dialysis, liver function was declining,” said Dr. Anand Srivastava, co-founder of GIOSTAR. “Nothing was working.”
The patient, whose identity is not being released due to privacy laws, had been in a coma in a New Jersey hospital. GIOSTAR got special clearance from the Food and Drug Administration to try the stem-cell treatment.
Srivastava said the patient began to recover, gradually over three weeks.
“Slowly, his renal and liver function came closer to normal,” he said. “He came out from the intubation, and now he is talking.”
The family, in an interview with GIOSTAR, said they had lost all hope.
Srivastava said this treatment could be key as society awaits a vaccine.
GIOSTAR is planning to do a double-blind study to confirm its conclusions about its treatment. It says that study should take about three months.
GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment
Promising results point to a potential alternative in combating the pandemic
SAN DIEGO, July 21, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program. As of July 14, 2020, there have been more than 13 million COVID-19 cases and over 500,000 deaths worldwide.
Contending with a Grim Prognosis
Under the direction of GIOSTAR Medical Director Dr. Prabhat Soni, a 53-year old male patient suffering from COVID-19 pneumonia was admitted to Saint Michael’s Medical Center in Newark, New Jersey, under the care of Dr. Richard Miller, MD, Chairman, Department of Pulmonary Medicine. The patient’s condition worsened over the course of the standard treatments, along with convalescent plasma therapy. He went into septic shock and his renal and hepatic functions continued to decline, requiring dialysis. The patient suffered a stroke, and remained in a coma at Saint Michael’s intensive care unit (ICU).
Improved Outcomesfroman Alternative Strategy
Noting the limited effectiveness of these measures, Dr. Soni designed a plan to treat the patient using stem cells. Research physician Dr. Michael J. DeMarco coordinated the plan, with day-to-day care provided to the patient by Dr. Miller and his Critical Care fellows Dr. Rutwik Patel and Dr. Harish Sharma, at Saint Michael’s.
Following treatment with AlloRx Stem Cells® from Vitro Biopharma, a Colorado-based company, the patient began recovery from multiple organ failure and a coma of almost 7 weeks. He had excellent recovery of his pulmonary, liver, and renal functions, ultimately coming off dialysis and ventilator support.
The patient’s recovery of neuro-muscular functions is evident in improved clarity of speech, ease of swallowing food, and many other everyday functions. Additionally, the elevated levels of inflammation markers seen prior to stem cell therapy have come down to within normal range. The patient was finally discharged from ICU, and is undergoing physical therapy with strong hopes of complete recovery.
COVID-19 and Mesenchymal Stem Cells (MSCs)
COVID-19 infection leads to uncontrolled release of proinflammatory cytokines – known as “cytokine storms” – that potentially leads to fatal damage of many organs of the body. “MSCs have specific characteristics that, when infused in the bloodstream,” explained Dr. Srivastava, “neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.”
Next Steps for Treatment of COVID-19
“We got outstanding results after using MSCs on our first patient,” noted Dr. Soni, “with similar results being reported by other institutions.” Dr. Srivastava states that “the use of MSCs may be a great option not only for critically ill COVID-19 patients, but also for those who may have risk of exposure. MSCs may prevent people from aggravations of the infection, thereby potentially saving lives while lowering the load on hospitals and the economy.” Drs. Srivastava and Soni emphasize that a placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.
GIOSTAR is the pioneer and established leader in the field of stem cell research. Under the leadership of Co-Founders Dr. Anand Srivastava and Mr. Deven Patel, the San Diego-based Institute has a tradition of groundbreaking research in stem cell science spanning over two decades.
Mesenchymal Stem Cells May Be A Credible Alternative Therapy To Fight With COVID-19 Pandemic
Coronavirus disease 2019 (COVID-19), a highly contagious disease, is propelled by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First identified in December 2019 in Wuhan quickly forced the World Health Organization (WHO) to declare the 2019–20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC)on 29 January 2020 and a pandemic on 11 March 2020.1-3 Following the emergence global powers are scrambling in search of reliable treatments urgently, and vaccines for future use. The deathly pathogenic virus has caused more than 3 million cases and two thousand deaths worldwide by April 29th, inciting the fear that the numbers may continue to increase. Common symptoms of COVID-19 include, but are not limited to, fever, cough, fatigue, shortness of breath, and loss of smell sense. Severe additional symptoms included in the list but not limited to are difficulty in breathing, persistent chest pain, confusion, and difficulty in waking up.While many cases only display mild symptoms, others may manifest a form of viral pneumonia leading to multi-organ failure and could be fatal.4-6 The viral infection causes a vicious release of different proinflammatory cytokines or a cytokine storm thought to be the root cause of organ failures.5 The virus has been recorded to spread between humans following a close contact with someone who has been infected,via small droplets that come from coughing or sneezing.Many humans can also get infected by being even in the vicinity of an infected person or after coming in contact of a contaminated surface and thentouching their face. The standard method of diagnosis and testing used by many countries is the method of real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging isalso helpfulduring the diagnosis stage; however, CDC guidelines do not recommend chest scans for routine screening.
COVID-19 affects the lungs the most, because the virus attacks host cells via the angiotensin-converting enzyme 2 receptor (ACE2). ACE2 is found on the surface of different cell types but type II alveolar cells present in the lungs are very rich in its content. The virus has a surface glycoprotein called a “spike” (peplomer) which helps in accessing the ACE2 and invade the host cell. Therefore, density of ACE2 in the cells of a tissue is related to with the severity of the effect of the infection. Considering its role in infection, many scientists have hypothesized that decreasing ACE2 activity might have positive effects in inhibiting infection. Though an opposing view also exists according to which increasing ACE2 activity by using angiotensin II receptor blocker may be protective.Both of these ideas need to be rigorously tested before either of these could be a guiding force for developing a therapeutic intervention. When the alveolar disease begins to progress, respiratory failure may begin and death may result. The virus also attacks gastrointestinal organs as ACE2 is present.
Currently, there is no available vaccine or specific antiviral treatment for COVID-19. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures. Because of the emergent need, medical professionals have rushed
Approval of MSCs for therapeutic is gaining acceptance around the globe.In Japan, MSCs have been approved for the treatment of another clinical condition called graft-versus-host disease.There are other such pending approvals in the US also as a number of clinical trials starting to test the benefits of MSCs for treating COVID-19 are at different stages.Many scientists, on the basis of the immune- modulatory ability of MSCs and other circumstantial evidence, think that MSCs should alleviate the symptoms in COVID-19 patients. It was evident by the Chinese study, which was reported in “Aging and Disease” last month also.The findings based on seven COVID-19 patients who received intravenous infusions of MSCs recovered successfully and were discharged from the hospital by the end of the 14-day observation period. In contrast, of the three patients of the control group receiving regular treatment, all of whom had severe disease, one died, one developed ARDS, and one achieved a stable condition.7,8
Many scientists see that MSCs could be a very promising approach for treatment of COVID-19 patients though the findings are based on a small number of subjects.Other scientists also think that the report demonstrates that the MSCs are not only well received by the patients but also impart a great therapeutic relief. Following the recent approval by FDA of the treatment for extreme cases and trials together with the recruitment of COVID-19 patients to existing MSC trials for ARDS around the world a significant amount of data will demonstrate the therapeutic value of allogenic stem cell-based treatments in COVID-19 patients. Reviewing all the developing data, we suggest that clinicians may safely use MSCs to manage those patients who are in severe condition. MSCs may also be used as a credible preventive therapy to make the immune system ready to fight the virus in case of any possible COVID-19 infection.
Prabhat Soni, Anand Srivastava
Global Institute of Stem Cell Therapy and Research (GIOSTAR),
Global Institute of Stem Cell Therapy and Research (GIOSTAR),
4660 La Jolla Village Drive, San Diego, CA, 92122, USA,
Received: May 01, 2020 | Published: June 11, 2020
1. Symptoms of Coronavirus. U.S. Centers for Disease Control and Prevention (CDC).
2. Q&A on coronaviruses (COVID-19). World Health Organization (WHO).
3. Hopkins, Claire. Loss of sense of smell as marker of COVID-19 infection. Ear, Nose and Throat surgery body of United Kingdom.
4. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
5. Puja Mehta, Daniel F McAuley, Michael Brown, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034.
6. “Q&A on coronaviruses”. World Health Organization (WHO).
7. Gu Jinyang, Han Bing, Wang Jian. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission”. Gastroenterology.
8. Leng Zikuan, Zhu Rongjia, Hou Wei, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease. 2020;11(2):216–228.